<DOC>
	<DOCNO>NCT00280761</DOCNO>
	<brief_summary>RATIONALE : Studying sample tumor tissue patient cancer laboratory may help doctor learn change occur DNA identify biomarkers related cancer . It may also help doctor understand patient respond treatment . PURPOSE : This clinical trial study biomarkers patient rectal cancer undergo chemotherapy radiation therapy .</brief_summary>
	<brief_title>Biomarkers Patients With Rectal Cancer Undergoing Chemotherapy Radiation Therapy</brief_title>
	<detailed_description>OBJECTIVES : Primary - Observe whether NF-kappa B activate response treatment external beam radiotherapy . - Correlate NF-kappa B pathway activation ( presumed anti-apoptotic nature ) therapeutic outcome ( measure rate pathologic complete response downstaging endoscopic ultrasound [ EUS ] ) . Secondary - Study downstream event induce NF-kappa B activation . - Determine global gene expression profile baseline chemoradiotherapy . - Correlate change gene expression ( compare baseline gene expression pattern ) induce single dose external beam radiotherapy patient outcome ( measure pathologic response rate downstaging EUS ) . - Study downstream event related activation p53 response treatment radiotherapy . - Correlate p53 pathway-mediated event clinical outcome . OUTLINE : Patients receive fluorouracil capecitabine undergo radiotherapy surgery per standard care . Patients undergo tumor pinch biopsy baseline day 1 2 chemoradiotherapy . At time final surgical resection , portion remain rectal tumor liquid nitrogen bank . Patients deem surgical candidate evaluate transrectal ultrasound 6-8 week completion chemoradiotherapy ass ultrasound response ( downstaging versus downstaging ) . Tumor tissue sample analyze NF-kappa B pathway activation ; downstream event induce NF-kappa B activation ; change global gene expression ; p53 function ; apoptosis ; mRNA expression . Laboratory technique use include tissue microarray , ELISA , RNase protection assay , fluorescence semi-quantitative PCR , TUNEL , IHC , cDNA microarray analysis . If normal tissue biopsy available , whole blood may collect point patient remain study correlative analysis research related rectal cancer .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Must rectal sigmoidrectal junction adenocarcinoma confirm sigmoidoscopy pathologic diagnosis biopsy sample Inferior margin tumor le 15 cm anal verge rigid sigmoidoscopy level S12 surgery Candidate chemotherapy radiotherapy , define follow : Tumor stag T3 N12 rectal sonography Tumor occupy &gt; 40 % circumference rectum Tumor fix extra colonic structure determine digital rectal examination Tumor &lt; 5 cm sphincter mechanism Patient inoperable disease treat palliation Pelvic anastomotic recurrence previously resect rectal cancer Planning undergo chemotherapy radiotherapy No sigmoid carcinoma ( carcinoma proximal pelvic peritoneal reflection ) PATIENT CHARACTERISTICS : Not pregnant PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>adenocarcinoma rectum</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>stage II rectal cancer</keyword>
	<keyword>stage III rectal cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
</DOC>